JCI:ADAM28介导乳腺癌转移

2012-06-17 Beyond 生物谷

ADAM28属于ADAM基因家族的金属蛋白酶,能切割血管性血友病因子(vWF)和抑制VWF介导肿瘤细胞凋亡,从而提高肺转移,假如抑制其表达的话能大幅减少肺转移,最新研究成果发表在Journal of The National Cancer Institute杂志上。 ADAMs与肿瘤的生长发展联系在一起,ADAM28在乳腺癌和非小细胞肺癌中过度表达,但ADAM28介导转移的机制是未知的。 为了

ADAM28属于ADAM基因家族的金属蛋白酶,能切割血管性血友病因子(vWF)和抑制VWF介导肿瘤细胞凋亡,从而提高肺转移,假如抑制其表达的话能大幅减少肺转移,最新研究成果发表在Journal of The National Cancer Institute杂志上。

ADAMs与肿瘤的生长发展联系在一起,ADAM28在乳腺癌和非小细胞肺癌中过度表达,但ADAM28介导转移的机制是未知的。

为了弄清ADAM28的作用,Satsuki Mochizuki博士和同事筛选了ADAM28可能影响的蛋白,发现VWF是其主要作用的蛋白。ADAM28影响VWF诱导的细胞凋亡作用,在小鼠模型研究中发现其抑制后,人肺癌和乳腺癌细胞的肺转移能力减小。

研究人员发现抑制ADAM28的表达或活性能使得肺转移大幅减少,血管中肿瘤细胞凋亡增加。在这项研究中,研究数据表明VWF诱导许多人细胞癌、肺癌、乳腺癌等肿瘤细胞凋亡,但只有当这些肿瘤细胞低表达ADAM28后,上述现象才出现。研究人员指出该研究的局限性在于该模型不能模拟出自发的人类癌症转移的过程,但结果表明ADAM28有促进癌细胞增殖和自发转移到远处器官的双向作用

doi:10.1093/jnci/djs232
PMC:
PMID:

Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor

Satsuki Mochizuki, Kenji Soejima, Masayuki Shimoda, Hitoshi Abe, Aya Sasaki, Hirotaka James Okano, Hideyuki Okano and Yasunori Okada

Background A disintegrin and metalloproteinase 28 (ADAM28) is implicated in tumor growth and metastasis in human breast and non–small cell lung carcinomas. We explored the mechanism of ADAM28-mediated metastasis by searching for new substrates of ADAM28.

Methods We used a yeast two-hybrid system to screen the human lung cDNA library for ADAM28-binding proteins and identified von Willebrand factor (VWF) as a potential candidate. Binding was confirmed using yeast two-hybrid and protein binding assays, and ADAM28-mediated cleavage of VWF was analyzed by immunoblotting. Exogenous VWF-induced apoptosis in vitro was examined in human lung carcinoma (PC-9 and Calu-3), breast carcinoma (MDA-MB231 and MCF-7), renal cell carcinoma (Caki-2 and 769P), and hepatocellular carcinoma (HepG2) cells, and expression of ADAM28 was assessed by reverse transcription–polymerase chain reaction and immunoblotting. Effect on lung metastasis of PC-9 and MDA-MB231 cells was assessed by knockdown of ADAM28 expression using short hairpin RNAs (ADAM28-shRNA) and small interfering RNAs (ADAM28-siRNA), and inhibition of activity using neutralizing anti-ADAM28 antibody, in a mouse xenograft model by in vivo imaging (n = 9 mice per group). All statistical tests were two-sided.

Results ADAM28 could bind to and cleave native VWF. Cells with very low ADAM28 expression (MCF-7, 769P, and HepG2) were susceptible to VWF-induced apoptosis, whereas cells with high expression (PC-9, Calu-3, MDA-MB231, and Caki-2) were resistant. Knockdown of ADAM28 expression in PC-9 and MDA-MB231 cells by shRNA showed increased carcinoma cell apoptosis mainly in lung blood vessels and statistically significantly decreased lung metastasis at week 3 after injection (PC-9-control [n = 9 mice] vs PC-9-ADAM28-shRNA [n = 9 mice]: mean count = 198 × 106 vs 37 × 106 photons/s, difference = 161 × 106 photons/s, 95% confidence interval = 134 × 106 to 188 × 106 photons/s, P < .001). Similar inhibition of lung metastasis was observed with ADAM28-siRNA and anti-ADAM28 antibody.

Conclusion ADAM28 cleaves and inactivates proapoptotic VWF in carcinoma cells and enhances lung metastasis probably by promoting carcinoma cell survival within the blood vessels.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981950, encodeId=89dd1981950b7, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 10 18:03:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264443, encodeId=fa1a12644435d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590221, encodeId=ea45159022191, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981950, encodeId=89dd1981950b7, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 10 18:03:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264443, encodeId=fa1a12644435d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590221, encodeId=ea45159022191, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-06-19 般若傻瓜
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981950, encodeId=89dd1981950b7, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 10 18:03:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264443, encodeId=fa1a12644435d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590221, encodeId=ea45159022191, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]

相关资讯

ASCO:人参可缓解癌症所致疲劳

       英国《每日邮报》报道,美国梅奥诊所癌症中心的科学家经研究发现,人参能够缓解癌症导致的疲劳,给癌症患者带去福音。根据他们进行的研究,服用大剂量花旗参两个月可有效缓解癌症患者的疲劳症状,效用远远超过安慰剂。在美国临床肿瘤学会的年度会议上,科学家将公布他们的研究发现。(Abstract 9001)       &n

第三届中国女医师临床肿瘤学大会精彩内容集锦

       2012 年5 月11 日,由中国女医师协会临床肿瘤学专家委员会主办的第三届中国女医师临床肿瘤学大会在京召开。本次大会由工程院院士陈赛娟女士担任大会主席,克晓燕、沈琳、冯奉仪、李惠平教授担任执行主席,来自全国100 多位肿瘤学杰出女性专家参加了会议。会议得到了主办单位领导的大力支持,北京大学肿瘤医院季加孚院长、北京大学第三医院刘晓光副院长、中国

霍奇金淋巴瘤幸存者面临高乳腺癌风险

芝加哥(EGMN)—— 纽约纪念斯隆-凯特琳肿瘤中心的生物统计师Chaya S. Moskowitz博士在美国临床肿瘤学会(ASCO)年会上报告,儿童时期接受霍奇金淋巴瘤胸部放疗的女性患者乳腺癌风险远远高于以往公认水平。 多项研究提示,儿童时期接受胸部放疗的女性乳腺癌风险增高。为了更好地阐述这部分患者的乳腺癌风险,Moskowitz博士及其同事进行了这项研究。 这项来自儿童肿瘤幸存者研究(CC

Nature:全基因组分析芳香化酶抑制剂治疗乳腺癌的疗效差异

       由华盛顿大学圣路易斯分校领衔的研究团队发表了题为“Whole-genome analysis informs breast cancer response to aromatase inhibition”的文章,通过分析患有晚期乳腺癌患者的DNA序列,发现了不同癌症的标记,这将有助于预测雌激素降低治疗的疗效,并深入解析乳腺癌

JBC:NOG基因促进乳腺癌细胞骨转移

乳腺癌细胞经常从肿瘤原位组织侵入骨骼,导致病人的生存机会减少。这个转移过程是非常复杂的,乳腺癌细胞本身和骨环境等在这一过程中都发挥重要作用。近日,一项发表在Journal of Biological Chemistry杂志上的由西班牙生物医学研究所的研究人员完成的一项研究分析了乳腺癌细胞移植到骨的具体机制。 研究人员重点研究了骨骼发育中发挥重要作用的基因NOG。此前,NOG与前列腺癌骨转移的关联

Cancer Res.: 趋化因子及受体CCL5/CCR5促进乳腺癌转移

趋化因子CCL5及其受体CCR5在乳腺癌进展过程中的作用一直是个谜。5月25日Cancer Research 杂志在线发表了Marco Velasco-Velazquez等人的研究论文阐明了其中的奥秘。   研究者通过对2254个人乳腺癌标本的微阵列分析发现,在基底型和HER-2亚型的标本中CCL5和CCR5表达升高。表达CCR5的乳腺癌细胞亚群可响应CCL5信号,产生功能性改变。此